MedPath

ZEro Pacemaker Implantation Sutureless Aortic Valve Replacement Study

Not Applicable
Conditions
Aortic stenosis
I35.0
Registration Number
JPRN-jRCT1032230138
Lead Sponsor
Tabata Minoru
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients undergoing aortic valve replacement using the Perceval bioprosthetic valve for aortic stenosis or aortic stenosis cum regurgitation at institutions participating in this study will be eligible.

Selection Criteria
(1) Age 18 years or older at the time of consent
(2) Patients with aortic valve disease that can be treated with the commercially available Perceval bioprosthetic valve as determined by preoperative CT scan or transesophageal echocardiography.
3) Patients who are judged to be suitable for Perceval bioprosthetic valve based on their age, general condition, and comorbidities.
(iv) Patients who are eligible for 30-day postoperative follow-up
(5) Patients who have received a thorough explanation of their participation in this study, and who have given their free and voluntary written consent based on a thorough understanding of the study.

Exclusion Criteria

Exclusion Criteria
(1) Patients undergoing concomitant surgery other than coronary artery bypass surgery
(2) Patients undergoing preoperative pacemaker (including implantable cardioverter defibrillator) implantation
(3) Patients with a preoperative diagnosis of chronic atrial fibrillation or atrioventricular block of two or more degrees
(4) Patients with a contraindication to Perceval bioprosthetic valve treatment in the package insert
(5) Patients with congenital bicuspid aortic valve (Sievers type 0) or unicuspid aortic valve
(6) Patients with aortic aneurysm or dissection of the ascending aorta
(vii) Patients with active endocarditis, myocarditis, or sepsis
(viii) If the subject is already participating in another clinical trial that may confound the results of this study
(ix) Other cases in which the principal investigator determines that the subject is inappropriate as a research subject.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Implementation of permanent pacemaker implantation up to 30 days postoperatively (including reason, timing, and model of implantation)
Secondary Outcome Measures
NameTimeMethod
1) New atrioventricular block (2nd or 3rd degree) and left bundle branch block at 30 days postoperatively<br>2) Intraoperative membranous septal injury<br>3) Re-implantation of prosthetic valve due to migration of the Scherless bioprosthetic valve<br>4) Periprosthetic regurgitation (zero, trivial, mild, moderate, severe) assessed by transthoracic echocardiogram before discharge
© Copyright 2025. All Rights Reserved by MedPath